MX2023002064A - Produccion estereoselectiva de fosforamidatos de purina seleccionados. - Google Patents
Produccion estereoselectiva de fosforamidatos de purina seleccionados.Info
- Publication number
- MX2023002064A MX2023002064A MX2023002064A MX2023002064A MX2023002064A MX 2023002064 A MX2023002064 A MX 2023002064A MX 2023002064 A MX2023002064 A MX 2023002064A MX 2023002064 A MX2023002064 A MX 2023002064A MX 2023002064 A MX2023002064 A MX 2023002064A
- Authority
- MX
- Mexico
- Prior art keywords
- phosphoramidates
- stereoselective production
- selected purine
- purine
- stereoselective
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 230000000707 stereoselective effect Effects 0.000 title abstract 2
- -1 PURINE PHOSPHORAMIDATES Chemical class 0.000 title 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 150000008298 phosphoramidates Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/02—Phosphorylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Luminescent Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063067726P | 2020-08-19 | 2020-08-19 | |
| US202063074302P | 2020-09-03 | 2020-09-03 | |
| US202063094759P | 2020-10-21 | 2020-10-21 | |
| US202063129306P | 2020-12-22 | 2020-12-22 | |
| PCT/US2021/046778 WO2022040473A1 (en) | 2020-08-19 | 2021-08-19 | Stereoselective manufacture of selected purine phosphoramidates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002064A true MX2023002064A (es) | 2023-03-16 |
Family
ID=80323295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002064A MX2023002064A (es) | 2020-08-19 | 2021-08-19 | Produccion estereoselectiva de fosforamidatos de purina seleccionados. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230331751A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4200309A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7851034B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230053640A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115884977A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021327241A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3173661A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002064A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022040473A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115477679A (zh) | 2017-02-01 | 2022-12-16 | 阿堤亚制药公司 | 用于治疗丙型肝炎病毒的核苷酸半硫酸盐 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| AU2022291927A1 (en) | 2021-06-17 | 2024-01-04 | Atea Pharmaceuticals, Inc. | Advantageous anti-hcv combination therapy |
| CN116462728B (zh) * | 2021-12-15 | 2023-12-12 | 南京知和医药科技有限公司 | 一种抗病毒感染的嘌呤核苷衍生物及其药物组合物和用途 |
| US12065404B2 (en) | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| CN121628124B (zh) * | 2026-02-05 | 2026-04-10 | 山东鲁源化工科技有限公司 | 一种高热稳定性聚磷酸酯阻燃剂及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2870169A1 (en) * | 2012-07-03 | 2015-05-13 | Bristol-Myers Squibb Company | Process for preparing diastereomerically enriched phosphoramidate derivatives of nucleoside compounds for treatment of viral infections |
| FI3265102T3 (fi) * | 2015-03-06 | 2025-10-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoksi-2'-alfa-fluori-2'-beta-c-substituoituja-2-modifioituja-n6-substituoituja puriininukleotideja hcv-hoitoa varten |
| PT3512863T (pt) * | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
| US10874687B1 (en) * | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| WO2021173713A1 (en) * | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Highly active compounds against covid-19 |
-
2021
- 2021-08-19 WO PCT/US2021/046778 patent/WO2022040473A1/en not_active Ceased
- 2021-08-19 JP JP2023512073A patent/JP7851034B2/ja active Active
- 2021-08-19 AU AU2021327241A patent/AU2021327241A1/en active Pending
- 2021-08-19 EP EP21859165.9A patent/EP4200309A4/en active Pending
- 2021-08-19 CN CN202180051015.9A patent/CN115884977A/zh active Pending
- 2021-08-19 KR KR1020237008983A patent/KR20230053640A/ko active Pending
- 2021-08-19 CA CA3173661A patent/CA3173661A1/en active Pending
- 2021-08-19 MX MX2023002064A patent/MX2023002064A/es unknown
-
2023
- 2023-02-17 US US18/111,316 patent/US20230331751A1/en active Pending
-
2026
- 2026-04-07 JP JP2026062962A patent/JP2026117077A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7851034B2 (ja) | 2026-04-24 |
| JP2023538594A (ja) | 2023-09-08 |
| US20230331751A1 (en) | 2023-10-19 |
| JP2026117077A (ja) | 2026-07-14 |
| AU2021327241A1 (en) | 2023-04-20 |
| CN115884977A (zh) | 2023-03-31 |
| TW202214260A (zh) | 2022-04-16 |
| KR20230053640A (ko) | 2023-04-21 |
| EP4200309A1 (en) | 2023-06-28 |
| EP4200309A4 (en) | 2025-03-19 |
| CA3173661A1 (en) | 2022-02-24 |
| WO2022040473A1 (en) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002903A1 (es) | Inhibidores de cdk | |
| AR111247A1 (es) | Compuestos de dinucleótidos cíclicos modificados | |
| CO2022002637A2 (es) | Proceso de fabricación de moduladores de cftr | |
| CU20210035A7 (es) | Compuestos de azalactam como inhibidores de hpk 1 | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| CY1121851T1 (el) | Προφαρμακα toy alvocidib που εχουν αυξημενη βιοδιαθεσιμοτητα | |
| CU20200046A7 (es) | Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47 | |
| CY1121416T1 (el) | Yποκατεστημενοι νουκλεοζιτες, νουκλεοτιδια και αναλογα αυτων | |
| CL2022003360A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578) | |
| MX2019007995A (es) | Novedoso polipeptido y procedimiento de produccion de imp mediante el uso del mismo. | |
| ECSP19030134A (es) | Compuesto de piridina | |
| CL2020003065A1 (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes | |
| NZ631552A (en) | Compositions and methods for modulating hbv expression | |
| NZ630890A (en) | Microrna compounds and methods for modulating mir-122 | |
| MX2025002218A (es) | Metodos de tratamiento de tumores solidos que presentan alteraciones activadoras del gen fgfr3 | |
| MX2017006942A (es) | Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer. | |
| ECSP24003566A (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| MY183198A (en) | Gemcitabine prodrugs | |
| CL2025003792A1 (es) | Proceso para sintetizar derivados de naftiridina y sus compuestos intermedios. | |
| AU2016229966A8 (en) | Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | |
| MX2025003091A (es) | Metodo para producir derivado de heterociclideno acetamida | |
| CY1123469T1 (el) | Σχηματα δοσολογιας του melflufen για καρκινο | |
| NZ748592A (en) | Treatment for parkinson’s disease | |
| CO2020010306A2 (es) | Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado. | |
| CL2024000990A1 (es) | Métodos y composiciones para el tratamiento de la enfermedad renal poliquística |